Vaxcyte, Inc. (PCVX) – What Are Investment Firms Thinking About This Stock?

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $110.50.

Several research analysts have recently issued reports on PCVX shares. BTIG Research restated a “buy” rating and issued a $89.00 price target on shares of Vaxcyte in a research report on Monday, October 5th. Needham & Company LLC upped their price objective on Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, October 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 target price on shares of Vaxcyte in a report on Monday, October 12th. Finally, Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th.

Read Our Latest Report on PCVX

Vaxcyte Stock Down 2.8%

NASDAQ PCVX opened at $61.61 on Thursday. The stock’s 50 day simple moving average is $62.25 and its 200 day simple moving average is $57.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.56 and a quick ratio of 4.56. The firm has a market cap of $9.75 billion, a PE ratio of -7.64 and a beta of 1.31. Vaxcyte has a one year low of $42.40 and a one year high of $90.75.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter in the prior year, the company earned ($1.56) earnings per share. As a group, sell-side analysts forecast that Vaxcyte will post -7.51 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.92, for a total transaction of $182,760.00. Following the transaction, the chief accounting officer owned 27,860 shares of the company’s stock, valued at $1,697,231.20. This trade represents a 9.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $60.90, for a total transaction of $137,025.00. Following the transaction, the executive vice president owned 145,435 shares of the company’s stock, valued at approximately $8,856,991.50. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,692 shares of company stock valued at $5,185,985 in the last ninety days. 3.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently bought and sold shares of PCVX. Jupiter Topco LLC acquired a new position in shares of Vaxcyte in the 2nd quarter valued at $1,044,355,000. Janus Henderson Group PLC increased its position in shares of Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after buying an additional 3,188,687 shares in the last quarter. BlackRock Inc. acquired a new stake in Vaxcyte during the 2nd quarter worth $701,520,000. Wellington Management Group LLP raised its stake in Vaxcyte by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock worth $407,001,000 after buying an additional 1,386,968 shares during the period. Finally, Bellevue Group AG raised its stake in Vaxcyte by 17.8% during the 3rd quarter. Bellevue Group AG now owns 2,322,401 shares of the company’s stock worth $132,145,000 after buying an additional 350,466 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.

Further Reading

Analyst Recommendations for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.